Official guidance & reports
SGLT2 medicines: why ketogenic-diet safety needs context
JARDIANCE (empagliflozin) prescribing information and Medication Guide
Published
View source reference
This reference credits the original source. The plain-language summary on this page is by Fasting Free.
Saved only in this browser, after you choose Save.
Fasting Free source summary: https://fastingfree.com/education/dailymed-2026-empagliflozin/
PLAIN-LANGUAGE SUMMARY
What this source adds
The label identifies ketogenic diets, reduced food intake, illness, and volume depletion among conditions that can precipitate ketoacidosis. Glucose may be below the levels usually expected with ketoacidosis.
Keep these limits in view
This label does not quantify the risk of a particular diet or determine an individual’s suitability. Diet and medicine decisions require the prescribing clinician; the dossier provides no dose-change instructions.
Understand the context
- Evidence type
- Official prescription-drug labeling
- Population or scope
- People prescribed empagliflozin, an SGLT2 inhibitor
- Comparison
- Regulatory safety information; not a randomized comparison of diets
- Measured outcomes
- Ketoacidosis risk situations and symptoms; volume-depletion and hypoglycemia warnings.